Literature DB >> 32168038

Therapeutic targeting of the DNA damage response in prostate cancer.

Catherine H Marshall1, Emmanuel S Antonarakis.   

Abstract

PURPOSE OF REVIEW: The present article highlights the most common DNA repair gene mutations, using specific examples of individual genes or gene classes, and reviews the epidemiology and treatment implications for each one [with particular emphasis on poly-ADP-ribose polymerase (PARP) inhibition and PD-1 blockade]. RECENT
FINDINGS: Genetic and genomic testing have an increasingly important role in the oncology clinic. For patients with prostate cancer, germline genetic testing is now recommended for all men with high-risk and metastatic disease, and somatic multigene tumor testing is recommended for men with metastatic castration-resistant disease. The most common mutations that are present in men with advanced prostate cancer are in genes coordinating DNA repair and the DNA damage response.
SUMMARY: Although much of what is discussed currently remains investigational, it is clear that genomically-targeted treatments will become increasingly important for patients with prostate cancer in the near future and beyond.

Entities:  

Mesh:

Substances:

Year:  2020        PMID: 32168038      PMCID: PMC8147657          DOI: 10.1097/CCO.0000000000000617

Source DB:  PubMed          Journal:  Curr Opin Oncol        ISSN: 1040-8746            Impact factor:   3.645


  56 in total

Review 1.  Clinical implications of mismatch repair deficiency in prostate cancer.

Authors:  Ramy Sedhom; Emmanuel S Antonarakis
Journal:  Future Oncol       Date:  2019-06-25       Impact factor: 3.404

Review 2.  Synthetic lethal therapies for cancer: what's next after PARP inhibitors?

Authors:  Alan Ashworth; Christopher J Lord
Journal:  Nat Rev Clin Oncol       Date:  2018-09       Impact factor: 66.675

3.  Cyclin-Dependent Kinase 12, Immunity, and Prostate Cancer.

Authors:  Emmanuel S Antonarakis
Journal:  N Engl J Med       Date:  2018-09-13       Impact factor: 91.245

4.  DNA-Repair Defects and Olaparib in Metastatic Prostate Cancer.

Authors:  Joaquin Mateo; Suzanne Carreira; Shahneen Sandhu; Susana Miranda; Helen Mossop; Raquel Perez-Lopez; Daniel Nava Rodrigues; Dan Robinson; Aurelius Omlin; Nina Tunariu; Gunther Boysen; Nuria Porta; Penny Flohr; Alexa Gillman; Ines Figueiredo; Claire Paulding; George Seed; Suneil Jain; Christy Ralph; Andrew Protheroe; Syed Hussain; Robert Jones; Tony Elliott; Ursula McGovern; Diletta Bianchini; Jane Goodall; Zafeiris Zafeiriou; Chris T Williamson; Roberta Ferraldeschi; Ruth Riisnaes; Bernardette Ebbs; Gemma Fowler; Desamparados Roda; Wei Yuan; Yi-Mi Wu; Xuhong Cao; Rachel Brough; Helen Pemberton; Roger A'Hern; Amanda Swain; Lakshmi P Kunju; Rosalind Eeles; Gerhardt Attard; Christopher J Lord; Alan Ashworth; Mark A Rubin; Karen E Knudsen; Felix Y Feng; Arul M Chinnaiyan; Emma Hall; Johann S de Bono
Journal:  N Engl J Med       Date:  2015-10-29       Impact factor: 91.245

5.  Pan-Cancer Analysis of CDK12 Loss-of-Function Alterations and Their Association with the Focal Tandem-Duplicator Phenotype.

Authors:  Ethan S Sokol; Dean Pavlick; Garrett M Frampton; Jeffrey S Ross; Vincent A Miller; Siraj M Ali; Tamara L Lotan; Drew M Pardoll; Jon H Chung; Emmanuel S Antonarakis
Journal:  Oncologist       Date:  2019-07-10

6.  PARP inhibition - not all gene mutations are created equal.

Authors:  Jun Luo; Emmanuel S Antonarakis
Journal:  Nat Rev Urol       Date:  2019-01       Impact factor: 14.432

7.  Safety, activity, and immune correlates of anti-PD-1 antibody in cancer.

Authors:  Suzanne L Topalian; F Stephen Hodi; Julie R Brahmer; Scott N Gettinger; David C Smith; David F McDermott; John D Powderly; Richard D Carvajal; Jeffrey A Sosman; Michael B Atkins; Philip D Leming; David R Spigel; Scott J Antonia; Leora Horn; Charles G Drake; Drew M Pardoll; Lieping Chen; William H Sharfman; Robert A Anders; Janis M Taube; Tracee L McMiller; Haiying Xu; Alan J Korman; Maria Jure-Kunkel; Shruti Agrawal; Daniel McDonald; Georgia D Kollia; Ashok Gupta; Jon M Wigginton; Mario Sznol
Journal:  N Engl J Med       Date:  2012-06-02       Impact factor: 91.245

8.  Familial Risk and Heritability of Cancer Among Twins in Nordic Countries.

Authors:  Lorelei A Mucci; Jacob B Hjelmborg; Jennifer R Harris; Kamila Czene; David J Havelick; Thomas Scheike; Rebecca E Graff; Klaus Holst; Sören Möller; Robert H Unger; Christina McIntosh; Elizabeth Nuttall; Ingunn Brandt; Kathryn L Penney; Mikael Hartman; Peter Kraft; Giovanni Parmigiani; Kaare Christensen; Markku Koskenvuo; Niels V Holm; Kauko Heikkilä; Eero Pukkala; Axel Skytthe; Hans-Olov Adami; Jaakko Kaprio
Journal:  JAMA       Date:  2016-01-05       Impact factor: 56.272

9.  Integrative clinical genomics of advanced prostate cancer.

Authors:  Dan Robinson; Eliezer M Van Allen; Yi-Mi Wu; Nikolaus Schultz; Robert J Lonigro; Juan-Miguel Mosquera; Bruce Montgomery; Mary-Ellen Taplin; Colin C Pritchard; Gerhardt Attard; Himisha Beltran; Wassim Abida; Robert K Bradley; Jake Vinson; Xuhong Cao; Pankaj Vats; Lakshmi P Kunju; Maha Hussain; Felix Y Feng; Scott A Tomlins; Kathleen A Cooney; David C Smith; Christine Brennan; Javed Siddiqui; Rohit Mehra; Yu Chen; Dana E Rathkopf; Michael J Morris; Stephen B Solomon; Jeremy C Durack; Victor E Reuter; Anuradha Gopalan; Jianjiong Gao; Massimo Loda; Rosina T Lis; Michaela Bowden; Stephen P Balk; Glenn Gaviola; Carrie Sougnez; Manaswi Gupta; Evan Y Yu; Elahe A Mostaghel; Heather H Cheng; Hyojeong Mulcahy; Lawrence D True; Stephen R Plymate; Heidi Dvinge; Roberta Ferraldeschi; Penny Flohr; Susana Miranda; Zafeiris Zafeiriou; Nina Tunariu; Joaquin Mateo; Raquel Perez-Lopez; Francesca Demichelis; Brian D Robinson; Marc Schiffman; David M Nanus; Scott T Tagawa; Alexandros Sigaras; Kenneth W Eng; Olivier Elemento; Andrea Sboner; Elisabeth I Heath; Howard I Scher; Kenneth J Pienta; Philip Kantoff; Johann S de Bono; Mark A Rubin; Peter S Nelson; Levi A Garraway; Charles L Sawyers; Arul M Chinnaiyan
Journal:  Cell       Date:  2015-05-21       Impact factor: 41.582

10.  Prospective Comprehensive Genomic Profiling of Primary and Metastatic Prostate Tumors.

Authors:  Jon H Chung; Ninad Dewal; Ethan Sokol; Paul Mathew; Robert Whitehead; Sherri Z Millis; Garrett M Frampton; Gennady Bratslavsky; Sumanta K Pal; Richard J Lee; Andrea Necchi; Jeffrey P Gregg; Primo Lara; Emmanuel S Antonarakis; Vincent A Miller; Jeffrey S Ross; Siraj M Ali; Neeraj Agarwal
Journal:  JCO Precis Oncol       Date:  2019-05-10
View more
  2 in total

1.  SLC26A4 correlates with homologous recombination deficiency and patient prognosis in prostate cancer.

Authors:  Cong Luo; Zhi Liu; Yu Gan; Xiaomei Gao; Xiongbing Zu; Ye Zhang; Wenrui Ye; Yi Cai
Journal:  J Transl Med       Date:  2022-07-14       Impact factor: 8.440

2.  Homologous recombination deficiency (HRD) score in germline BRCA2- versus ATM-altered prostate cancer.

Authors:  Tamara L Lotan; Harsimar B Kaur; Daniela C Salles; Sanjana Murali; Edward M Schaeffer; Jerry S Lanchbury; William B Isaacs; Robert Brown; Andrea L Richardson; Olivier Cussenot; Geraldine Cancel-Tassin; Kirsten M Timms; Emmanuel S Antonarakis
Journal:  Mod Pathol       Date:  2021-01-18       Impact factor: 8.209

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.